Veracyte, Inc. (VCYT) delivered first-quarter 2025 earnings of 31 cents per share, which marked a stupendous improvement of 63.2% from the year-ago period’s figure of 19 cents. The bottom line beat the Zacks Consensus Estimate by 55%.The company-adjusted earnings per share (EPS) were 9 cents compared to the year-ago period’s loss of 2 cents per share. Following the earnings announcement, VCYT’s share price gained 1.2% yesterday. VCYT’s Q1 RevenuesRevenues increased 18.3% year over year to $114.5 million, wh ...

Veracyte (VCYT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a changing ear ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36156 VERACYTE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I ...

Veracyte (VCYT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 55%. A quarter ago, it was expected that this molecular diagnostic company would post earnings of $0.29 per share when it actually produced earnings of $0.36, delivering a surprise of 24.14%. Over the last four quarters, th ...

Veracyte (VCYT) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Speaker0 and thank you for standing by. Welcome to the Veracyte First Quarter twenty twenty five Financial Results Webcast. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Sheila Gorman, Senior Director, Investor Relations. P ...

veracyte. Q1 2025 Earnings Presentation May 7, 2025 2 © 2025 Veracvte. Inc. All rights reserved. © 2025 Veracyte, Inc. All rights reserved. 3 Forward-looking statements and non-GAAP information This presentation contains forward-kodoling, statements, including, but not lintied to our plans, dbjectives, and expectives, and expectabions (financial and othernise), i 2025 and 2020 fina vial and operating results our assumptions for future reveave royst: plans and friming of the release of version 2.0 cour' leng ...

Exhibit 99.1 Veracyte Announces First Quarter 2025 Financial Results Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 7, 2025 --- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by stron ...

Veracyte (VCYT) has consistently gained from the strength of its Afirma and Decipher tests. With Decipher expanding into metastatic and localized disease areas, the growth is likely to continue in the coming years. Simultaneously, the company continues to progress in its strategic long-term growth drivers. Meanwhile, declining biopharmaceutical revenues and macroeconomic impacts raise concerns for its operations. In the past year, this Zacks Rank #2 (Buy) stock has demonstrated impressive performance, outpe ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? Developed along ...

After reaching an important support level, Veracyte (VCYT) could be a good stock pick from a technical perspective. VCYT surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.The 20-day simple moving average is a well-liked trading tool because it provides a look back at a stock's price over a 20-day period. Additionally, short-term traders find this SMA very beneficial, as it smooths out short-term price trends and shows more trend reversal signals than longer-term moving ...